300142 沃森生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)1.8094.5508.2955.69217.584
总资产报酬率 ROA (%)1.1122.7125.0233.67012.046
投入资产回报率 ROIC (%)1.6444.1787.8035.47117.278

边际利润分析
销售毛利率 (%)79.99685.47488.01888.61286.397
营业利润率 (%)13.14514.92521.61520.51146.828
息税前利润/营业总收入 (%)17.43712.83519.80719.35545.682
净利润/营业总收入 (%)17.96612.43018.44617.36641.211

收益指标分析
经营活动净收益/利润总额(%)91.717160.534119.595117.80874.735
价值变动净收益/利润总额(%)-35.419-38.004-17.519-31.43620.774
营业外收支净额/利润总额(%)32.149-2.503-2.707-0.188-0.217

偿债能力分析
流动比率 (X)2.9392.7262.5502.3743.362
速动比率 (X)2.5442.4032.2662.1043.022
资产负债率 (%)22.86426.90128.34026.8780.186
带息债务/全部投入资本 (%)4.6394.1201.4260.063-3.079
股东权益/带息债务 (%)1,966.1602,196.5716,535.940151,499.450-3,169.446
股东权益/负债合计 (%)275.524222.946209.008230.844365.545
利息保障倍数 (X)-9.001-7.437-15.997-17.309-43.736

营运能力分析
应收账款周转天数 (天)382.338292.173214.357233.085154.118
存货周转天数 (天)640.855611.627552.109619.485358.645